Prevail Therapeutics (PRVL) Misses Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Prevail Therapeutics (PRVL) Misses Q2 EPS by 7c

Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

August 11, 2020 6:31 AM EDT

Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinsons Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients

Company Modifies Protocol for PROPEL Trial of PR001 for Parkinsons Disease Patients with GBA1 Mutations; Expects to Continue Enrollment in Second Half of 2020

PROVIDE Trial of PR001 for Type 2 Gaucher Disease and PROCLAIM Trial of PR006 for Frontotemporal Dementia Patients with GRN Mutations Expected to Initiate Enrollment in Second Half of 2020

$75.0 Million At-The-Market Equity Program
... More